Elranatamab for Relapsed/Refractory Multiple Myeloma With Severe Renal Impairment Requiring Hemodialysis [0.03%]
复发/难治性多发性骨髓瘤并重度肾损害需血液透析患者中艾兰他单抗的疗效
Michèle Hoffmann,Barbara Jeker,Uyen Huynh-Do et al.
Michèle Hoffmann et al.
Relapsed/refractory multiple myeloma (RRMM) patients with dialysis-dependent renal impairment face limited therapeutic options due to exclusion from clinical trials, a lack of evidence-based guidelines, and inferior outcomes. Bispecific ant...
Case Reports
Hematological oncology. 2025 Jul;43(4):e70120. DOI:10.1002/hon.70120 2025
Deubiquitinase TRIM44 Promotes Autophagy-Mediated Chemoresistance in Diffuse Large B Cell Lymphoma [0.03%]
去泛素化酶TRIM44通过促进自噬介导弥漫性大B细胞淋巴瘤的化疗耐药
Yan Wang,Banban Li,Yanan Zhao et al.
Yan Wang et al.
Diffuse large B cell lymphoma (DLBCL) is the most common subtype of non-Hodgkin lymphoma. Tripartite motif containing 44 (TRIM44) belonging to the TRIM family, is involved in tumor development and is highly expressed in a variety of tumors....
Impact of Body Composition on Treatment Toxicity and Outcomes in Patients With Primary Mediastinal Large B-Cell Lymphoma [0.03%]
体成分对原发纵隔大B细胞淋巴瘤患者治疗毒性和结局的影响
Juliette Penichoux,Pierre Decazes,Cédric Rossi et al.
Juliette Penichoux et al.
Primary mediastinal large B-cell lymphoma (PMBL) is a rare entity that predominantly affects young female patients and typically presents as a large and compressive anterior mediastinal mass. Accumulating evidence suggests relationships amo...
Multicenter Study
Hematological oncology. 2025 Jul;43(4):e70117. DOI:10.1002/hon.70117 2025
A Novel Prognostic Score for Disease Progression and Mortality in Patients With Newly Diagnosed Primary Large B-Cell Lymphoma of Immune-Privileged Sites [0.03%]
免疫隔离部位新诊断原发性大B细胞淋巴瘤患者疾病进展和死亡的新预后评分模型
Ganggang Wang,Jiesong Wang,Cong Sun et al.
Ganggang Wang et al.
Primary large B-cell lymphoma of immune-privileged sites (IP-LBCL), a recently defined entity in WHO-HAEM5, includes primary diffuse large B-cell lymphoma (DLBCL) occurring in immune-privileged areas like the central nervous system (PCNS-LB...
Risk Stratification for Diffuse Large B-Cell Lymphoma by Integrating Interim 18F-FDG PET-CT Analysis and the NCCN-IPI: A Multicenter Retrospective Study [0.03%]
基于中期18F-FDG PET-CT影像学整合NCCN-IPI的弥漫大B细胞淋巴瘤预后分层模型：多中心回顾性研究
Jiesong Wang,Yong Sun,Meifu Lin et al.
Jiesong Wang et al.
Our study aimed to assess the prognostic significance of the interim National Comprehensive Cancer Network International Prognostic Index and PET-CT-related parameters for predicting patient outcomes and achieving precise risk stratificatio...
Multicenter Study
Hematological oncology. 2025 Jul;43(4):e70118. DOI:10.1002/hon.70118 2025
The Efficacy and Safety of the Addition of Mitoxantrone Hydrochloride Liposome in Conditioning Regimen for High-Risk Acute Myeloid Leukemia [0.03%]
米托蒽醌脂质体联合表阿霉素和Bu组成的预处理方案治疗高危AML患者的疗效及安全性分析
Xiaoyu Zhang,Donglin Yang,Aiming Pang et al.
Xiaoyu Zhang et al.
Despite allo-HSCT being the primary curative treatment for high-risk AML, relapse-free survival (RFS) remains suboptimal due to high relapse incidence. Our research focuses on optimizing the conditioning regimen by incorporating Mitoxantron...
Exploratory Analysis of Practical Predictive Indices for the Efficacy of Mogamulizumab in Patients With Aggressive Adult T-Cell Leukemia-Lymphoma [0.03%]
探索性分析月森利珠单抗治疗成人T细胞白血病淋巴瘤的疗效预测指标
Yutaka Shimazu,Kenta Murotani,Hiroki Kitabayashi et al.
Yutaka Shimazu et al.
An exploratory analysis of past clinical trials was conducted to propose a predictive scoring system for the efficacy of mogamulizumab, an anti-CC chemokine receptor 4 (CCR4) antibody, based on easily measurable parameters. Factors affectin...
Clinical Trial
Hematological oncology. 2025 Jul;43(4):e70114. DOI:10.1002/hon.70114 2025
Safety and Efficacy of Low-Dose Venetoclax Plus Voriconazole in Patients With Acute Myeloid Leukemia Unfit for Intensive Chemotherapy [0.03%]
低剂量维奈克拉联合伏立康唑治疗不适合接受强化化疗的急性髓系白血病患者的疗效和安全性
Xinyao Liu,Danchen Meng,Yuxin Li et al.
Xinyao Liu et al.
Low-dose venetoclax plus strong CYP3A4 inhibitor voriconazole were commonly used for acute myeloid leukemia (AML) patients who were unfit for intensive chemotherapy in China. However, the efficacy and safety of this schedule have not been w...
Clinical Outcome of Extramedullary Multiple Myeloma in the Era of Novel Agents: Insights From a Multicenter Study [0.03%]
新型治疗药物时代髓外多发性骨髓瘤的临床转归及多中心研究心得
Dong Liang,Yurong Yan,Qiaoli Wang et al.
Dong Liang et al.
This study aimed to discuss the clinical outcomes of extramedullary multiple myeloma in the era of novel agents, based on the largest dataset regarding extramedullary multiple myeloma in China. This study included 597 patients without extra...
Multicenter Study
Hematological oncology. 2025 Jul;43(4):e70112. DOI:10.1002/hon.70112 2025
Primary Extranodal Follicular Lymphoma: A Retrospective Survey of the International Extranodal Lymphoma Study Group (IELSG) [0.03%]
原发性结外滤泡淋巴瘤：国际结外淋巴瘤研究组的回顾性调查研究
Annarita Conconi,Andrea Janikova,Barbara Vannata et al.
Annarita Conconi et al.
The characteristics at diagnosis and clinical course of primary extranodal follicular lymphoma (EFL) have not been extensively described. The International Extranodal Lymphoma Study Group (IELSG) conducted an international retrospective sur...